Multiple Myeloma

News alerts, weekly reports and conference planners

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + ixazomib Sensitive: A1 - Approval Oncology Central - 1 week (New A2) lenalidomide + ixazomib Sensitive : A1 Oncology Central - 1wk	lenalidomide + ixazomib Sensitive: A1 - Approval Oncology Central - 1 week lenalidomide + ixazomib Sensitive : A1 Oncology Central - 1 week - (New A2)
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	carfilzomib Sensitive: A1 - Approval carfilzomib Sensitive : A1	carfilzomib Sensitive: A1 - Approval carfilzomib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib + panobinostat Sensitive: A1 - Approval bortezomib + panobinostat Sensitive : A1	bortezomib + panobinostat Sensitive: A1 - Approval bortezomib + panobinostat Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval bortezomib + pegylated liposomal doxorubicin Sensitive : A1	bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval bortezomib + pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	SVd Sensitive: A1 - Approval SVd Sensitive : A1	SVd Sensitive: A1 - Approval SVd Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	ciltacabtagene autoleucel Sensitive: A1 - Approval ciltacabtagene autoleucel Sensitive : A1	ciltacabtagene autoleucel Sensitive: A1 - Approval ciltacabtagene autoleucel Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide Sensitive: A1 - Approval pomalidomide Sensitive : A1	pomalidomide Sensitive: A1 - Approval pomalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	thalidomide Sensitive: A1 - Approval thalidomide Sensitive : A1	thalidomide Sensitive: A1 - Approval thalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	isatuximab-irfc Sensitive: A1 - Approval isatuximab-irfc Sensitive : A1	isatuximab-irfc Sensitive: A1 - Approval isatuximab-irfc Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	prednisone + thalidomide + melphalan Sensitive: A1 - Approval prednisone + thalidomide + melphalan Sensitive : A1	prednisone + thalidomide + melphalan Sensitive: A1 - Approval prednisone + thalidomide + melphalan Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + daratumumab/hyaluronidase Sensitive: A1 - Approval lenalidomide + daratumumab / hyaluronidase Sensitive : A1	lenalidomide + daratumumab/hyaluronidase Sensitive: A1 - Approval lenalidomide + daratumumab / hyaluronidase Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + elotuzumab Sensitive: A1 - Approval lenalidomide + elotuzumab Sensitive : A1	lenalidomide + elotuzumab Sensitive: A1 - Approval lenalidomide + elotuzumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + daratumumab Sensitive: A1 - Approval lenalidomide + daratumumab Sensitive : A1	lenalidomide + daratumumab Sensitive: A1 - Approval lenalidomide + daratumumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	selinexor Sensitive: A1 - Approval selinexor Sensitive : A1	selinexor Sensitive: A1 - Approval selinexor Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	daratumumab/hyaluronidase Sensitive: A1 - Approval daratumumab / hyaluronidase Sensitive : A1	daratumumab/hyaluronidase Sensitive: A1 - Approval daratumumab / hyaluronidase Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib Sensitive: A1 - Approval bortezomib Sensitive : A1	bortezomib Sensitive: A1 - Approval bortezomib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	VTD Sensitive: A1 - Approval VTD Sensitive : A1	VTD Sensitive: A1 - Approval VTD Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	belantamab mafodotin Sensitive: A1 - Approval belantamab mafodotin Sensitive : A1	belantamab mafodotin Sensitive: A1 - Approval belantamab mafodotin Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	denosumab Sensitive: A1 - Approval denosumab Sensitive : A1	denosumab Sensitive: A1 - Approval denosumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	melphalan flufenamide Sensitive: A1 - Approval melphalan flufenamide Sensitive : A1	melphalan flufenamide Sensitive: A1 - Approval melphalan flufenamide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + isatuximab-irfc Sensitive: A1 - Approval pomalidomide + isatuximab-irfc Sensitive : A1	pomalidomide + isatuximab-irfc Sensitive: A1 - Approval pomalidomide + isatuximab-irfc Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + carfilzomib Sensitive: A1 - Approval lenalidomide + carfilzomib Sensitive : A1	lenalidomide + carfilzomib Sensitive: A1 - Approval lenalidomide + carfilzomib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	daratumumab + pomalidomide Sensitive: A1 - Approval daratumumab + pomalidomide Sensitive : A1	daratumumab + pomalidomide Sensitive: A1 - Approval daratumumab + pomalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	daratumumab Sensitive: A1 - Approval daratumumab Sensitive : A1	daratumumab Sensitive: A1 - Approval daratumumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	isatuximab-irfc Sensitive: A1 - Approval isatuximab-irfc Sensitive : A1	isatuximab-irfc Sensitive: A1 - Approval isatuximab-irfc Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	idecabtagene vicleucel Sensitive: A1 - Approval idecabtagene vicleucel Sensitive : A1	idecabtagene vicleucel Sensitive: A1 - Approval idecabtagene vicleucel Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	zoledronic acid Sensitive: A1 - Approval zoledronic acid Sensitive : A1	zoledronic acid Sensitive: A1 - Approval zoledronic acid Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	daratumumab + thalidomide Sensitive: A1 - Approval daratumumab + thalidomide Sensitive : A1	daratumumab + thalidomide Sensitive: A1 - Approval daratumumab + thalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	thalidomide + daratumumab/hyaluronidase Sensitive: A1 - Approval thalidomide + daratumumab / hyaluronidase Sensitive : A1	thalidomide + daratumumab/hyaluronidase Sensitive: A1 - Approval thalidomide + daratumumab / hyaluronidase Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + daratumumab/hyaluronidase Sensitive: A1 - Approval pomalidomide + daratumumab / hyaluronidase Sensitive : A1	pomalidomide + daratumumab/hyaluronidase Sensitive: A1 - Approval pomalidomide + daratumumab / hyaluronidase Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	teclistamab Sensitive: A1 - Approval teclistamab Sensitive : A1	teclistamab Sensitive: A1 - Approval teclistamab Sensitive : A1

Multiple Myeloma

Associations(380)

Associations
(380)